familial adenomatous polyposis PreCancer Atlas Attempts to Push Precision Medicine to Early-Stage Disease Premium Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form. Colorectal Cancer Clues Provided by Polyp Profiles Investigators identified mutation, expression, and methylation differences in colorectal polyps from individuals with or without colorectal cancer. Hereditary Colorectal Cancer Syndrome Caused by Recessive Mutations in Mismatch Repair Gene Researchers identified two cases with biallelic mutations in MSH3 in exome sequences from more than 100 patients with unexplained colorectal adenomatous polyposis. Colorectal Adenoma Exomes Reveal Precancerous Somatic Mutation In individuals at risk of colorectal cancer, pre-cancerous adenomas contain somatic mutations affecting known cancer genes and pathways. Marina Aims to Restart FAP Trial by Year End Premium Restarting the trial will require the company to raise additional funds before its money runs out this summer. Aug 22, 2013 With a Leaner Structure and Maturing Technologies, Marina Looks to Rebuild Premium May 30, 2013 As Big Pharma Looks to Niche Diseases, RNAi May Benefit Premium Jan 26, 2012 Marina Preps for Additional Patient Enrollment in FAP Trial, Predicts Pharma Partnership This Year Premium Apr 21, 2011 Marina Completes Enrollment of First Cohort in FAP Drug Trial Premium Mar 17, 2011 Marina Biotech Advances FAP Drug into Phase I Premium Mar 3, 2011 Marina Says Primate Data Shows FAP Drug Safety Premium Jan 6, 2011 Marina Receives Orphan Drug Designation for FAP Drug, Notice of Allowance for Delivery Patent Application Premium Nov 18, 2010 Marina Pipeline on Track with FAP Trial in 2010, But Could Miss Partnership Guidance Premium Nov 4, 2010 Marina Gets Institutional Approval to Begin Phase I Study of FAP Drug Premium Oct 28, 2010 Marina Says Initial Tox Data Shows FAP Drug to be Safe Premium Apr 15, 2010 Cequent Begins Long-Term Tox Study with FAP Drug Premium Dec 10, 2009 FDA OKs Cequent IND for Oral RNAi Drug Premium Oct 29, 2009 Cequent Says In-House IBD Candidate Will Likely Move to Clinic Before Novartis-Optioned Rx Premium Feb 12, 2009 Cequent Releases Primate Safety, Efficacy Data for Oral FAP Therapy Premium Breaking News Singular Genomics Systems Reports No Revenues, Increased Net Loss for Q2 Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib Gene Editing Analysis Firm SeQure Dx Closes $17.5M Series A Funding Round Resolve Biosciences, Zeiss Partner to Enhance Spatial Biology Imaging Tech EliTechGroup Obtains CE Mark for Saliva Use With SARS-CoV-2 Test Waters Q2 Revenues Up 31 Percent The Scan And Back The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database. Lacks Family Hires Attorney A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports. For the Unknown The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona. PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.